Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Cardiovascular diseases in spondyloarthritis (literature review)
https://doi.org/10.33667/2078-5631-2024-29-56-60
Abstract
Spondyloarthritis is a group of diseases involving the axial skeleton and sacroiliac joints, including axial spondyloarthritis or ankylosing spondylitis and peripheral spondyloarthritis. Spondyloarthritis is associated with an increase in cardiovascular morbidity and mortality, which may be the result of cardiac manifestations of disease or due to the accelerated development of atherosclerosis. The combination of two pathologies contributes to a more severe course of diseases and negatively affects the results of therapy, which indicates the relevance of this interdisciplinary problem. The review highlights data on cardiovascular morbidity and mortality in spondyloarthritis, the occurrence of various risk factors. The data on the relationship of cardiovascular pathology with activity and functional disorders in spondyloarthritis are presented.
About the Authors
P. V. Koroy
Stavropol State Medical University
Russian Federation
Russian Federation
Pavel V. Koroy, DM Sci (habil.), porofessor, professor at Dept
Dept of Hospital Therapy
Stavropol
N. N. Gladkikh
Stavropol State Medical University
Russian Federation
Russian Federation
Natalia N. Gladkikh, DM Sci (habil.), professor
Dept of Hospital Therapy
Stavropol
A. V. Yagoda
Stavropol State Medical University
Russian Federation
Russian Federation
Alexander V. Yagoda, DM Sci (habil.), professor, head of Dept
Dept of Hospital Therapy
Stavropol
T. R. Dudov
Stavropol State Medical University
Russian Federation
Russian Federation
Temirlan R. Dudov, assistant
Dept of Hospital Therapy
Stavropol
S. A. Kozakova
Stavropol State Medical University
Russian Federation
Russian Federation
Svetlana A. Kozakova, PhD Med, associate professor
Dept of Hospital Therapy
Stavropol
References
1. Bosch P., Zhao S. S., Nikiphorou E. The association between comorbidities and disease activity in spondyloarthritis – a narrative review. Best Pract. Res. Clin. Rheumatol. 2023; 37 (3): 101857. doi: 10.1016/j.berh.2023.101857
2. Dey M., Nagy G., Nikiphorou E. Comorbidities or extra-articular manifestations: time to reconsider the terminology? Rheumatology. 2022; 61 (10): 3881e3. doi: 10.1093/rheumatology/keac134
3. Gupta S., Syrimi Z., Hughes D. M. et al. Comorbidities in psoriatic arthritis : a systematic review and meta-analysis. Rheumatol. Int. 2021; 41 (2): 275e84. doi: 10.1007/s00296-020-04775-2
4. Zhao S. S., Robertson S., Reich T. et al. Prevalence and impact of comorbidities in axial spondyloarthritis : systematic review and meta-analysis. Rheumatology. 2020; 59: iv47e57. doi: 10.1093/rheumatology/keaa246
5. Bhattad P., Kulkarni M., Patel P. D. et al. Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus. 2022; 14 (6): e25633. doi: 10.7759/cureus.25633
6. Kim J. H., Choi I. A. Cardiovascular morbidity, and mortality in patients with spondylarthritis: a meta-analysis. Int. J. Rheum. Dis. 2020; 24 (4): 477–486. doi: 10.1111/1756-185X.13970
7. Yagoda A. V., Gladkih N. N. Endocardium and heart valves in systemic rheumatic diseases. Stavropol: StGMU; 2021: 384. (In Russ.).
8. Lai Y., Zhang Y., Mo S. et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann. Rheum. Dis. 2022; 81: e43. doi: 10.1136/annrheumdis-2020-217313
9. Redeker I., Callhoff J., Hoffmann F. et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res. Ther. 2020; 22 (1): 210. doi: 10.1186/s13075-020-02301-0
10. Gökşenoğlu G., Buğdaycı D., Paker N. et al. The prevalence of comorbidity and predictors in ankylosing spondylitis. Turk. J. Phys. Med. Rehabil. 2019; 65 (2): 132–138. doi: 10.5606/tftrd.2019.2822
11. Godzenko A. A., Korsakova Yu.O., Rumyantseva O. A. et al. Progression of aortic and valvular heart diseases in patients with ankylosing spondylitis. Rheumatology Science and Practice. 2017; 55 (5): 509–513. (In Russ.). doi: 10.14412/1995-4484-2017-509-513
12. Longo B., Kirchner L. A., Simioni J. et al. Electrocardiographic changes in spondyloarthritis and use of anti-TNF-α drugs: a retrospective study with 100 patients. Einstein (Sao Paulo). 2019; 17: eAO4539. doi: 10.31744/einstein_journal/2019AO4539
13. Bengtsson K., Klingberg E., Deminger A. et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019; 5: e001053. doi: 10.1136/rmdopen-2019-001053
14. Сay H. F., Alkan Melikoğlu M., Yurdakul F. G. et al. Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar. Arch. Rheumatol. 2023; 38 (3): 333–346. doi: 10.46497/ArchRheumatol.2023.9793
15. Llop M., Gratacуs J., Moreno M. et al. Sex differential impact of comorbidities in spondyloarthritis: data from COMOSPA study. RMD Open. 2024; 10: e003776. doi: 10.1136/rmdopen-2023-003776
16. Bengtsson K., Forsblad-d’Elia H., Lie E. et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res. Ther. 2017; 19: 102. doi: 10.1186/s13075-017-1315-z
17. Eriksson J. K., Jacobsson L., Bengtsson K. et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann. Rheum. Dis. 2017; 76 (2): 364–370. doi: 10.1136/annrheumdis-2016-209315
18. Saidov Yo.U., Odilzoda I. Yo., Khasanzoda S. M. et al. The prevalence of traditional cardiovascular risk factors in patients with rheumatoid and in those with psoriatic arthritis. Rheumatology Science and Practice. 2020; 58 (2): 165–170. (In Russ.). doi: 10.14412/1995-4484-2020-165-170
19. Moltó A., Nikiphorou E. Comorbidities in spondyloarthritis. Front. Med. 2018; 5: 62. doi: 10.3389/fmed.2018.00062
20. Rueda-Gotor J., Llorca J., Corrales A. et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin. Exp. Rheumatol. 2016; 34: 885–892.
21. López-Medina C., Molto A. Comorbidity management in spondyloarthritis. RMD Open. 2020; 6: e001135. doi: 10.1136/rmdopen-2019-001135
22. Arévalo M., López-Medina C., Moreno Martinez-Losa M. et al. Role of HLA-B 27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine. 2020; 87 (5): 445–448. doi: 10.1016/j.jbspin.2020.03.012
23. Walsh J. A., Song X., Kim G., Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J. Pharm. Health. Serv. Res. 2018; 9 (2): 115–121. doi: 10.1111/jphs.12212
24. Exarchou S., Lie E., Lindström U. et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann. Rheum. Dis. 2016; 75: 1466–1472. doi: 10.1136/annrheumdis-2015-207688
25. Kerola A. M., Kazemi A., Rollefstad S. et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology. 2022; 61 (12): 4656e66. doi: 10.1093/rheumatology/keac210
26. Turina M. C., Yeremenko N., van Gaalen F. et al. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open. 2017; 3: e000319. doi: 10.1136/rmdopen-2016-000319
27. Skov L., Thomsen S. F., Kristensen L. E. et al. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br. J. Dermatol. 2019; 180 (1): 100e7. doi: 10.1111/bjd.16919
28. van der Heijde D., Wei J. C., Dougados M. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018; 392: 2441–451. doi: 10.1016/S0140-6736(18)31946-9
29. Batkaeva N. V., Korotaeva T. V., Batkaev E. A. The pattern of cardiovascular comorbidity in patients with severe forms of psoriasis: Data of retrospective analysis of a hospital cohort. Rheumatology Science and Practice. 2017; 55 (5): 493–499. (In Russ.). doi: 10.14412/1995-4484-2017-493-499
30. Derakhshan M. H., Goodson N. J., Packham J. C. et al. Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J. Rheumatol. 2019; 46 (7): 701–709. doi: 10.3899/jrheum.180538
31. Liew J. W., Ward M. M., Reveille J. D. et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res. 2020; 72 (11): 1645e52. doi: 10.1002/acr.24070
32. Tibuakuu M., Kamimura D., Kianoush S. et al. The association between cigarette smoking and inflammation: the Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One. 2017; 12: e0184914. doi: 10.1371/journal.pone.0184914
33. Gisondi P., Fostini A. C., Fossà I. et al. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018; 36 (1): 21–28. doi: 10.1016/j.clindermatol.2017.09.005
34. Wibetoe G., Ikdahl E., Rollefstad S. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 2017; 19: 153. doi: 10.1186/s13075-017-1358-1
35. Gkolfinopoulou C., Stratikos E., Theofilatos D. et al. Impaired antiatherogenic functions of high-density lipoprotein in patients with ankylosing spondylitis. J. Rheumatol. 2015; 42: 1652–1660. doi: 10.3899/jrheum.141532
36. van der Heijde D., Ramiro S., Landewé R. et al. 2016 update of the ASAS-EULAR management recom-mendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76 (6): 978–991. doi: 10.1136/annrheumdis-2016-210770
37. Genre F., Rueda-Gotor J., Quevedo-Abeledo J.C. et al. Insulin resistance in non-diabetes patients with spondyloarthritis. Scand. J. Rheumatol. 2020; 49 (6): 476–483. doi: 10.1080/03009742.2020.1751272
38. Kumthekar A., Ogdie A. Obesity and psoriatic arthritis : a narrative review. Rheumatol. Ther. 2020; 7 (3): 447e56. doi: 10.1007/s40744-020-00215-6
39. Bindesbøll C., Garrido-Cumbrera M., Bakland G. et al. Obesity increases disease activity of Norwegian patients with axial spondyloarthritis: results from the European map of axial spondyloarthritis survey. Curr. Rheumatol. Rep. 2020; 22(8): 43. doi: 10.1007/s11926-020-00917-4
40. Liew J. W., Huang I. J., Louden D. N. et al. Association of body mass index on disease activity in axial spondyloarthritis : systematic review and meta-analysis. RMD Open. 2020; 6 (1): e001225. doi: 10.1136/rmdopen-2020–001225
41. Ortolan A., Lorenzin M., Felicetti M. et al. Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res. 2021; 73 (12): 1815e25. doi: 10.1002/acr.24416
42. Walsh J. A., Wan M. T., Willinger C. et al. Measuring outcomes in psoriatic arthritis: comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J. Rheumatol. 2020; 47 (10): 1496e505. doi: 10.3899/jrheum.190219
43. Garrido-Cumbrera M., Gálvez-Ruiz D., Delgado-Domínguez C.J. et al. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 2021; 7 (3): e001769. doi: 10.1136/rmdopen-2021–001769
44. Zhao S. S., Radner H., Siebert S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology. 2019; 58 (10): 1746e54. doi: 10.1093/rheumatology/kez119
45. Zhao S. S., Miller N., Harrison N. et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin. Rheumatol. 2020; 39 (1): 217e25. doi: 10.1007/s10067-019-04734-8
46. Zhao S. S., Jones G. T., Hughes D. M. et al. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology. 2021; 60 (12): 5734e42. doi: 10.1093/rheumatology/keab242
47. Cai M., Liu W., Wu Y. et al. The serum uric acid is longitudinally related to patients global assessment of disease activity in male patients with axial spondyloarthritis BMC Musculoskelet Disord. 2022; 23 (1): 717. doi: 10.1186/s12891-022-05657-3
48. Sargın B., Gurer G., Boztaş G. T., Ozturk H. Association between serum uric acid and inflammation markers in ankylosing spondylitis patients treated with tumor necrosis factor-α or nonsteroidal anti-inflammatory drugs. Eur. Res. J. 2019; 5 (1): 104–108. doi: 10.18621/eurj.359504
49. Lai Y., Zhang Y., Lei Z. et al. Association between serum uric acid concentration and radiographic axial spondylarthritis: a cross-sectional study of 202 patients. Chin. Med. J. 2023; 136: 1114–1116. doi: 10.1097/CM9.0000000000002148
Review
For citations:
Koroy P.V., Gladkikh N.N., Yagoda A.V., Dudov T.R., Kozakova S.A. Cardiovascular diseases in spondyloarthritis (literature review). Medical alphabet. 2024;(29):56-60. (In Russ.) https://doi.org/10.33667/2078-5631-2024-29-56-60
Views:
130
Email this article 